T .			
	•	m	$\boldsymbol{\alpha}$
1.4	a	ш	С.

## **Enrolment No:**



## **UPES**

## **End Semester Examination, December 2023**

Course: Design of Clinical Trials, Conduct, Audit and Compliance Semester : Vth **Program: Int BMSC Clinical Research Duration** : 3 Hours Max. Marks: 100

**Course Code: HSCR3013** 

Instructions: All questions are compulsory. Please attempt all.

S. No.	Section A	Marks	COs
	Short answer questions/ MCQ/T&F		
	(20Qx1.5M=30 Marks)		
Q 1	Phase 1 of clinical trial is usually done to explore the safety of the	1.5	CO1
	treatment. (True/False)		COI
Q 2	Microdosing studies are also known as phase 0 studies.	1.5	CO1
	(True/False)		
Q 3	Define Single blind study.	1.5	CO1
Q 4	What is a placebo?	1.5	CO1
Q 5	Define inclusion and exclusion criteria?	1.5	CO2
Q 6	What is case report form?	1.5	CO2
Q 7	Which document is mandatory to enroll subject in clinical research	1.5	CO2
	study?		
	a. Protocol		
	b. Case Report Form		
	c. Informed Consent Form		
	d. Investigators Brochure		
Q 8	finances the study.	1.5	CO2
	a. Sponsor		
	b. Regulatory body		
	c. Ethics committee		
	d. Investigator		
Q 9	Conflict of interest is a risk factor for scientific misconduct in	1.5	CO3
	clinical research studies. (True/False)		
Q 10	Adverse Drug Reaction reporting is mandatory in clinical trials.	1.5	CO3
	(True/False)		
Q 11	How many people will be selected for phase II trial?	1.5	CO3
	a) The whole market will be under surveillance		
	b) 500-3000 people		
	c) 100-300 people		
	d) 20-50 people		

0.10	D' FDA' ' CA A' 1 1 A	1.7	002
Q 12	During FDA inspection of the trial regulatory records are	1.5	CO3
0.12	reviewed. (True/False)	1.7	CO.4
Q 13	According to ICH GCP (International Conference on	1.5	CO4
	Harmonization - Good Clinical Practice) guidelines, which		
	document outlines the objective(s), design, methodology,		
	statistical considerations, and organization of a clinical trial?		
	a. Informed Consent Form		
	b. Investigator's Brochure		
	c. Clinical Study Protocol		
	d. Case Report Form		
Q 14	Although a subject is not obliged to give his/her reason(s) for	1.5	CO4
	withdrawing prematurely from a trial, the investigator should make		
	a reasonable effort to ascertain the reason(s), while fully respecting		
	the subject's rights.(True/False)		
Q 15	Clinical trials should be conducted in accordance with the ethical	1.5	CO4
	principles that are consistent with GCP and the applicable		
	regulatory requirement(s), and that have their origin in the		
	Declaration of		
	a. Clinical Research Regulations		
	b. Independence		
	c. Geneva Conference		
	d. Helsinki		
Q 16	What is SOPs?	1.5	CO4
Q 17	Name the body regulating clinical trials in India.	1.5	CO5
Q 18	A CAPA is a response to findings from an audit or inspection.	1.5	CO5
	What does the C stand for?		
	a. Current		
	b. Corrective		
	c. Compliance		
	Coordinated		
Q 19	Surrogate endpoint is	1.5	CO5
<b>Q</b> 27	a. A subjective endpoint	1.0	
	b. A measurement that is used in place of another measure		
	that is more difficult to assess		
	c. A measurement derived from a combination of		
	assessments		
	A point at which the trial could be stopped for safety reasons		
Q 20	Write full form of ANOVA	1.5	CO5
Q 20	WITE THI TOTH OF ANOVA	1.3	CO3

	Section B		
	(4Qx5M=20 Marks)		
Q 1	Write the important considerations of clinical trials for CVS disorders.	5	CO 1
Q 2	Discuss in brief about case report form.	5	CO 1
Q 3	Enumerate importance of informed consent form in Clinical trials.	5	CO 2
Q 4	Support the following statement The SOPs are integral part of documentation in clinical trials.	5	CO3
	Section C		
	(2Qx15M=30 Marks)		
Q 1	Explain in detail about adaptive design in clinical trials.	15	CO 4
Q 2	Give outline of auditing process in clinical trials and justify the importance of auditing in clinical trials by giving suitable examples.	15	CO 5
	Section D		
	(2Qx10M=20 Marks)		
Q 1	Discuss in detail about Patient and Protocol compliance in clinical trials	10	CO 2
Q 2	Classify various clinical trial designs. Explain each design by giving suitable explanation.	10	CO3